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Abstract
Motor dysfunction, particularly ataxia, is one of the predominant clinical manifestations in patients with
multiple sclerosis (MS). Assessment of motor dysfunction suffers from a high variability. We investi-
gated whether the clinical rating of ataxia can be improved through the use of reference videos, covering
the spectrum of severity degrees as defined in the Neurostatus-Expanded Disability Status Scale.
Twenty-five neurologists participated. The variability of their assessments was significantly lower
when reference videos were used (SD¼ 0.12; range¼ 0.40 vs SD¼ 0.26; range¼ 0.88 without reference
videos; p¼ 0.013). Reference videos reduced the variability of clinical assessments and may be useful
tools to improve the precision and consistency in the clinical assessment of motor functions in MS.
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Introduction
In multiple sclerosis (MS) clinical assessment
scales—mainly the Expanded Disability Status
Scale (EDSS)—are used to quantify impairment
and disability. The EDSS is known for a low inter-
and intrarater reliability and suffers from a high var-
iability, especially at lower EDSS scores.1 Motor
dysfunction and particularly ataxia is one of the pre-
dominant clinical manifestations in patients with MS
and a major contributor to disability progression.2
Thus, reliable and consistent rating of ataxia is cru-
cial for the follow-up of patients with MS.
Objective
The objective of this report is to investigate whether
reference videos (RVs) exemplifying degrees of
ataxia severity can reduce the variability of motor
dysfunction assessment in MS.
Methods
Study design and participants
This study was a subproject of “Assess MS,”3 a
study approved by the local ethics committees.
All patients gave their written informed consent to
the video recordings. Twenty-five raters (neurolo-
gists) from the university hospitals in Bern and
Basel rated 60 videos based on 43 MS patients per-
forming the finger-to-nose test (FNT). The videos
were recorded with a Microsoft KinectTM 1 camera
and chosen out of >2000 videos recorded for the
Assess MS study, with the constraint to have cover-
age for all limb ataxia grades of the Neurostatus-
EDSS definitions.4,5 According to these definitions
there are five grades of limb ataxia: 0¼ no ataxia,
1¼ signs only, 2¼ tremor or clumsy movements
easily seen, minor interference with function,
3¼ tremor or clumsy movements interfere with
function in all spheres and 4¼most functions are
very difficult. The ratings were performed at base-
line and six weeks later (“retest”), to assess the long-
term intrarater agreement. In both rating sessions
10% of the videos were presented twice for short-
term intrarater agreement.
Forty-one RVs, different from the videos used for
rating, were chosen by experienced neurologists of
the Assess MS study. They also showed MS patients
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performing the FNT, with different degrees of limb-
ataxia severity, based on the Neurostatus-EDSS def-
initions.4,5 The raters were randomized into two
groups: one group assessing videos based only on
the written Neurostatus-EDSS definitions,5 without
simultaneous access to the RVs (Setting 1), and the
other, with simultaneous access to the RVs
(Setting 2). The characteristics of the raters are sum-
marized in Table 1. There was no difference in expe-
rience with MS patients between the groups
(Setting 1 vs Setting 2).
Patient performance
For FNT videos, MS patients were instructed by the
recording neurologists of the Assess MS study to
close their eyes and abduct their arms to 90 degrees
at the shoulder in full extension, before touching the
nose with the tip of their index finger, first with
the dominant, then with the nondominant side
(Figure 1).
Video rating
Videos were presented for rating on a touchscreen.
Setting 2 allowed for simultaneous presentation of
RVs on the right part of the screen (Figure 1).
Horizontal swipe allowed for viewing RVs of differ-
ent limb-ataxia severity degrees; vertical swipe for
viewing alternative RVs of the same severity degree.
In Setting 1 this part of the screen remained black.
Raters were allowed to view each video as often as
required for scoring.
Statistics
The analysis was conducted using Matlab R2014b
(MathWorks, Natick, MA, USA). F test was used to
compare the variability of the ratings between the
two rater groups (Setting 1 vs Setting 2). Interrater
agreement was calculated as intraclass correlation
coefficient (ICC) for single measurements and abso-
lute agreement.6 Intrarater agreement was calculated
as the percentage of identical ratings.
Results
The variability of ratings was significantly lower in
Setting 2 (standard deviation (SD)¼ 0.12; range =
0.40) than in Setting 1 (SD¼ 0.26; range¼ 0.88, F
test; p¼ 0.013), as illustrated in Figure 2. The ICC
for interrater agreement was numerically slightly
higher in Setting 2 (0.816 (95% confidence interval
(CI): 0.756–0.871) vs 0.756 (95% CI: 0.674–0.829)
in Setting 1) but this difference was not significant.
Short-term and long-term intrarater agreement were
similar across settings (Setting 1: 7918% and 69
11%; Setting 2: 7522% and 689%, not
significant).
The average score of limb ataxia (according to the
Neurostatus-EDSS definitions) was slightly higher
in Setting 2, with RVs (mean score (test and retest
after six weeks): 1.4 0.1 in Setting 2, vs 1 0.3 in
Setting 1, p< 0.0001), as illustrated in Figure 2. No
significant interaction was found between intrarater
agreement, raters’ experience with MS or EDSS
assessments, or the centers (data not shown).
Discussion
As “pars pro toto,” the results of this study show that
using preselected RVs can reduce the rating variabil-
ity in the assessment of limb ataxia of MS patients.
Table 1. Characteristics of patients and neurologists participating in this study.
Patients (n¼ 43)
Age, years, mean SD (range) 42.79 12.09 (23–77)
Gender (female/male) 29/14
Disease duration (years), mean SD (range) 13.25 8.38 (0.5–40)
Median EDSS (range) 3.5 (1–6.5)
MS type, n (%)
RRMS 39 (90.7%)
SPMS 3 (7%)
PPMS 1 (2.3%)
Neurologists (n ¼ 25) Group Setting 1 Group Setting 2
Gender (female/male) 7/6 5/7
Years of experience with MS, mean (range) 5.5 (0.5–12) 5.8 (0.2–12)
Years of experience with EDSS, mean (range) 5.0 (0.5–12) 5.6 (0.2–12)
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis;
RRMS: relapsing–remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis.
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The use of such videos can be easily implemented
and does not require an additional/new scale, since
we used the already well-established Neurostatus-
EDSS definitions.4 Whether this approach can also
be used for assessments other than limb ataxia
remains to be shown.
We found a small but statistically significant differ-
ence of the average severity level obtained in the two
settings with higher ratings in the setting with RVs.
As the ataxia degrees were assigned to the RVs by
neurologists with special expertise in clinical ratings,
this may have contributed to stricter interpretation of
Figure 2. On the left the ratings of Setting 1, i.e. the group without reference videos are shown without ((w/o) ref) and on
the right, those from Setting 2, i.e. the group with reference videos (“with ref”). Mean and standard deviation (SD) are
shown in green, median in magenta. The variability of ratings was significantly lower in Setting 2 (SD¼ 0.12;
range¼ 0.40) than in Setting 1, w/o) reference videos (SD¼ 0.26; range¼ 0.88, F test; p¼ 0.013). Each dot represents the
average of all ratings of one neurologist (blue at baseline and red six weeks later).
Figure 1. Reference videos on the right, videos to be rated on the left, below fields for scoring the appropriate severity of
the performance using ataxia grades of the Neurostatus-Expanded Disability Status Scale definitions. According to these
definitions there are five grades of limb ataxia: 0¼ no ataxia, 1¼ signs only, 2¼ tremor or clumsy movements easily
seen, minor interference with function, 3¼ tremor or clumsy movements interfere with function in all spheres and
4¼most functions are very difficult. People shown are not patients and gave written consent to be shown.
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the grade definitions. A further limitation in our
study was the low number of severely affected
patients (ataxia grades 3 and 4). In daily routine,
however, rating of lower-severity grades is more
challenging than higher grades. Our RV approach
may also have a role in training machine-learning
algorithms (MLAs). Such an example is the Assess
MS system, a potentially finer-grained tool to mea-
sure motor dysfunction in MS.3 This system uses
advanced MLAs to analyze three-dimensional-
depth-sensor recordings of MS patients performing
standard tests of motor function, like the FNT.
Reducing the variability of clinical assessments
that are used to train MLAs should also contribute
to improved algorithms that are derived from
machine learning.
Conclusions
The use of RVs may represent a simple method to
reduce variability in the assessment of motor dys-
function in MS. This method could be particularly
useful in the context of clinical research, and to
train MLAs.
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